Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients

This publication has 16 references indexed in Scilit:

• Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival
  Oncogene, 2001
• Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression
  JNCI Journal of the National Cancer Institute, 2001
• Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
  JNCI Journal of the National Cancer Institute, 2000
• Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas
  JNCI Journal of the National Cancer Institute, 2000
• Aberrant methylation of p16 ^INK4a is an early event in lung cancer and a potential biomarker for early diagnosis
  Proceedings of the National Academy of Sciences, 1998
• The H-cadherin ( CDH13 ) gene is inactivated in human lung cancer
  Human Genetics, 1998
• Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
  Proceedings of the National Academy of Sciences, 1996
• 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
  Nature Medicine, 1995
• Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients
  Oncology, 1989
• Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
  Cancer, 1983